• Disease
  • Soft
  • Soft Tissue
  • Jaap Verweij

    Prominent publications by Jaap Verweij

    KOL Index score: 18731

    Importance: Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes.

    Objective: To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival.

    Design, Setting, and Participants: Open-label, phase 3 ...

    Also Ranks for: Neoadjuvant Chemotherapy |  regional hyperthermia |  soft tissue |  95 patients |  eortc 62961
    KOL Index score: 18213

    BACKGROUND: Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with ...

    Also Ranks for: Doxorubicin Ifosfamide |  3 trial |  tissue sarcoma |  metastatic soft |  controlled phase
    KOL Index score: 18194

    BACKGROUND: The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.

    METHODS: Patients were recruited to ...

    Also Ranks for: Regional Hyperthermia |  chemotherapy patients |  phase 3 |  tissue sarcoma |  risk soft
    KOL Index score: 16419

    Most gastrointestinal stromal tumors (GISTs) harbor oncogenic mutations in KIT or platelet-derived growth factor receptor-α. However, a small subset of GISTs lacks such mutations and is termed ‘wild-type GISTs’. Germline mutation in any of the subunits of succinate dehydrogenase (SDH) predisposes individuals to hereditary paragangliomas and pheochromocytomas. However, germline mutations of the genes encoding SDH subunits A, B, C or D (SDHA, SDHB, SDHC or SDHD; collectively SDHx) are also ...

    Also Ranks for: Sdha Mutations |  gastrointestinal stromal |  sdhb immunohistochemistry |  sdhc sdhd |  type gists
    KOL Index score: 15000

    BACKGROUND: Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found the combination of the two drugs to be feasible. The EORTC ECSG performed a multicenter phase II study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck to evaluate the antitumor efficacy and toxicity of this combination.

    PATIENTS AND METHODS: Eligibility criteria included written informed consent, a WHO ...

    Also Ranks for: Squamous Cell |  head neck |  docetaxel cisplatin |  patients locally |  treatment toxicity
    KOL Index score: 13997

    PURPOSE: In in vitro studies, synergism and sequence-dependent effects were reported for the combination of topotecan and cisplatin. Recently, an oral formulation of topotecan became available. This phase I study was performed to assess the feasibility of the combination of oral topotecan and cisplatin, the pharmacokinetic interaction, and sequence-dependent effects.

    PATIENTS AND METHODS: Topotecan was administered orally (PO) daily for 5 days in escalating doses and cisplatin was given ...

    Also Ranks for: Oral Topotecan |  intravenous cisplatin |  pharmacologic study |  pharmacokinetic interaction |  drug administration
    KOL Index score: 13968

    CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types. In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (STS) were treated, 50 with CAELYX (50 mg/m(2) by a 1 h intravenous (i.v.) infusion every 4 weeks) and 44 with doxorubicin (75 mg/m(2) by an i.v. bolus every 3 weeks). Histological subtypes were evenly matched, 33% were leiomyosarcoma (CAELYX: ...

    Also Ranks for: Pegylated Liposomal Doxorubicin |  patients grade |  soft tissue |  bone sarcoma |  3 4
    KOL Index score: 13942

    Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world. A major impediment for the successful treatment is the development of drug resistance. The molecular processes that contribute to resistance have been extensively studied; however, there is not much known about regulation by microRNAs (miRNAs). We compared miRNA expression profiles of an isogenic cisplatin-sensitive and -resistant ovarian cancer cell line pair (A2780/A2780 DDP) and found 27 miRNAs ...

    Also Ranks for: Cisplatin Sensitivity |  mir141 keap1 |  ovarian cancer |  1 micrornas |  resistance neoplasm
    KOL Index score: 13891

    BACKGROUND: Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to ...

    Also Ranks for: Revised Recist |  new response |  tumour burden |  sum lesions |  special issue
    KOL Index score: 13858

    BACKGROUND: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin ...

    Also Ranks for: Cytochrome P450 |  irinotecan pharmacokinetics |  midazolam clearance |  erythromycin metabolism |  phytogenic area
    KOL Index score: 13739

    Previous clinical investigations with doxorubicin indicated that modulators of P-glycoprotein dramatically decrease the systemic clearance of the drug, which complicates the interpretation of toxicity and response data. In the present study, we examined the pharmacokinetics of doxorubicin and GF120918, a novel potent P-glycoprotein inhibitor, in cancer patients in a search for more selective modulation of multidrug resistance (MDR). Seven cohorts (46 patients) received sequential ...

    Also Ranks for: Doxorubicin Gf120918 |  multiple drug resistance |  combination treatment |  46 patients |  systemic clearance
    KOL Index score: 13556

    AIMS: The histopathological diagnosis of gastrointestinal stromal tumours (GIST) is typically made based on a combination of clinical and morphological features supported by immunohistochemistry studies. The aim of this study was to examine the staining quality, sensitivity, specificity and utility of antibodies used commonly in GIST diagnosis.

    METHODS AND RESULTS: Immunohistochemistry with a panel of antibodies [CD117, DOG1, protein kinase C (PKC)-theta, nestin, CD34, smooth muscle ...

    Also Ranks for: Gastrointestinal Stromal Tumours |  diagnosis gist |  dog1 cd117 |  sma desmin |  neoplasm proteins


    Jaap Verweij: Influence Statistics

    Sample of concepts for which Jaap Verweij is among the top experts in the world.
    Concept World rank
    urothelial cell cancer #1
    crel male patients #1
    antineoplastic agents xeloda #1
    p00001 kit exon #1
    bsa drug clearance #1
    theirsometimes #1
    aceporol riciporol #1
    largerpopulation #1
    ifosfamide adult patients #1
    wbc hepc #1
    inhibitors irinotecan #1
    ser112ala #1
    total drug levels #1
    taxanes vitro studies #1
    pathogenesis gist #1
    lorazepam cisplatin chemotherapy #1
    antibodies gist diagnosis #1
    antineoplastic agents cross #1
    cp471358 myalgia #1
    thrombocytopenia dose #1
    5fluorouracil tumor tissue #1
    docetaxel cancer patients #1
    capecitabine food #1
    knockdown rsk1 #1
    amax auc #1
    100 urine #1
    anc aoc #1
    model transitional probabilities #1
    xenograftswere #1
    6hour ivs neutropenia #1
    thrombocytopenia limiting toxicities #1
    combination cisplatin topotecan #1
    curve chromatography docetaxel #1
    imatinib nomograms #1
    955111 #1
    granisetron dexamethasone cycles #1
    anticancer drugs obese #1
    3 patients grade #1
    new active drug #1
    taxane pharmacology #1
    44 scheme scheme #1
    mtp dose #1
    gynaecological sarcomas #1
    3hour ivs fatigue #1
    tpt sn38 #1
    gcsf doselimiting toxicity #1
    neomycin arm #1
    sarcoma refractory #1
    grade 3 anorexia #1

    Key People For Soft Tissue

    Top KOLs in the world
    Christopher D M FLETCHER†
    soft tissue situ hybridization fibrous histiocytoma
    Murray, F Brennan
    gastric cancer soft tissue pancreatic adenocarcinoma
    Jean Michel Coindre
    soft tissue french sarcoma situ hybridization
    Cyril FISHER†
    soft tissue synovial sarcoma situ hybridization
    Cristina R Antonescu
    situ hybridization soft tissue gastrointestinal stromal
    James M Woodruff
    synovial sarcoma soft tissue 5 years

    Jaap Verweij:Expert Impact

    Concepts for whichJaap Verweijhas direct influence:Soft tissue,  Antineoplastic agents,  Solid tumors,  Soft tissue sarcomas.

    Jaap Verweij:KOL impact

    Concepts related to the work of other authors for whichfor which Jaap Verweij has influence:Breast cancer,  Cell lung,  Neoadjuvant chemotherapy,  Solid tumors,  Antineoplastic agents,  Tumor response,  Gastrointestinal stromal.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Erasmus MC Cancer Institute, Rotterdam, the Netherlands. | Department of Medical Oncology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands;, jaap@cddf.org | Dept Medical Oncology, Erasmus University Medical Center, R